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Abstract
Purpose—Long-term (LT) androgen suppression (AS) with RT is a standard treatment for high-
risk, localized prostate cancer (PCa). RTOG 9902 was a randomized trial testing the hypothesis 
that adjuvant combination chemotherapy (CT) with paclitaxel, estramustine, and oral etoposide 
(TEE) + LT AS+ RT would improve overall survival (OS).
Materials and Methods—High-Risk PCa patients (PSA 20–100 and Gleason score (GS) ≥7 or 
clinical stage ≥T2 and GS ≥8) were randomized to RT and AS (AS+RT) alone or with adjuvant 
CT (AS+RT+CT). CT was four 21-day (d) cycles, delivered beginning 28d after 70.2 Gy RT. AS 
was: LHRH for 24 months (mo) beginning 2 mo prior to RT plus oral anti-androgen for 4 mo 
before and during RT. The study was designed based on a 6% improvement in OS from 79% to 
85% at 5 years, with 90% power and a 2-sided alpha of 0.05.
Results—397 patients (380 eligible) were randomized. The patients had high-risk PCa, 68% 
having Gleason Score 8–10, and 34% T3–T4 tumors, and median PSA of 22.6 ng/ml. Median 
follow-up is 9.2 years. The trial closed early because of excess thromboembolic toxicity in the CT 
arm. 10-year results for all randomized patients revealed no significant difference in AS+RT vs. 
AS+RT+CT in OS (65% vs. 63%; p=0.81); Biochemical Failure (BF) (58% vs. 54%; p=0.82); 
Local Progression (LP) (11% vs. 7%; p=0.09); Distant Metastases (DM) (16% vs. 14%; p=0.42); 
or Disease-Free Survival (DFS) (22% vs. 26%; p=0.61).
Conclusions—NRG Oncology RTOG 9902 showed no significant difference in OS, BF, LP, 
DM, or DFS with the addition of adjuvant CT to LT AS + RT. The trial provides valuable data 
regarding the natural history of high-risk PCa treated with LT AS + RT, and has implications for 
the feasibility of clinical trial accrual and tolerability utilizing CT in PCa.
Introduction
Prostate cancer is the most common malignancy in men, and the second most common cause 
of male cancer death in the US.1 Although prostate cancer specific mortality is low in 
studies of low and intermediate risk prostate cancer patients2,3 there is significant mortality 
for men with high-risk prostate cancer.4
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The Radiation Therapy Oncology Group (RTOG) has studied the strategy of combining 
androgen suppression (AS) with radiation therapy (RT). In RTOG 8531, the 10 year disease-
free survival (DFS) rate for patients treated with RT alone was only 9%, and was 
significantly improved with the addition of AS.5 Trials from the European Organization for 
Research and Treatment of Cancer (EORTC) showed improved survival for poor prognosis 
prostate cancer patients treated with AS+RT vs. patients treated with RT alone.6,7
RTOG 9202 compared a short term regimen AS (2 mo prior to RT and then 2 mo concurrent 
with RT) with the same regimen followed by long-term (LT, 2 years) AS following RT. For 
the subset of patients with Gleason Score 8–10 cancers, there was a significant overall 
survival (OS) benefit noted for LT AS + RT. For patients treated on the LT AS + RT arm of 
RTOG 9202, the overall biochemical failure rate was 52%, and DFS was 23%, indicating 
room for further therapeutic improvement8,9 Bolla et al. from the EORTC also demonstrated 
that a regimen of 3 years of AS + RT resulted in improved survival when compared with 6 
months of AS + RT.10
Risk stratification models were developed which used pre-treatment variables such as PSA, 
Gleason Score, and clinical tumor (T) stage to identify patients who were high-risk for 
recurrence.11 Based on these models, in RTOG 9902, a group of high risk patients was 
identified to test the hypothesis that more intensive treatment upfront, employing cytotoxic 
chemotherapy (CT), could reduce the number of patients who recurred and result in 
improved survival when compared with AS and RT alone. Clones which were resistant to 
initial treatment with AS and RT could be potentially eradicated by CT. CT was to be 
delivered as an adjuvant following RT. A combination of paclitaxel, estramustine and oral 
etoposide (TEE), which had shown promise in Phase II studies, was selected as the CT 
regimen.12 The primary objective of the trial was to determine if the addition of CT to LT 
AS + RT would result in improved OS compared with LT AS + RT only.
Materials and Methods
Patient Population
Patients eligible for inclusion on RTOG 9902 were men with high risk, but clinically and 
radiographically non-metastatic prostate cancer. Eligibility criteria included histologically 
confirmed prostate cancer with PSA 20–100 ng/ml and Gleason Score (GS) ≥ 7 with any T-
Stage, or clinical T-Stage ≥T2 and GS 8–10 with any PSA≤100. Patients were required to 
have negative lymph nodes by CT or MR, and no evidence of distant metastasis. Patients 
with imaging positive LN were to be confirmed negative by biopsy. Bone scan was required 
prior to entry. Baseline PSA, testosterone, hematologic, liver, and renal function studies 
were required. Zubrod performance status was 0–1. No prior pelvic RT or orchiectomy was 
allowed. Prior AS was allowed only if started no greater than 30 days prior to protocol entry. 
Medical oncology consultation was required prior to protocol entry to ensure that patients 
would be suitable candidates if randomized to chemotherapy. Institutional Review Board 
(IRB) was obtained at each participating center.
Patients were followed during the first 2 years of treatment with PSA and other laboratory 
values every 3 months and then every 6 months for 3 years and annually thereafter. Patients 
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were followed weekly during the course of radiation therapy, and were reassessed prior to 
each cycle of chemotherapy.
Treatment Schema
All patients were treated with LT (two years) androgen suppression (AS) and RT. AS and 
RT were identical on both arms. Patients were randomized to receive long-term AS and RT 
alone (AS+RT) or to receive long-term AS, RT, and 4 cycles of chemotherapy (CT) with 
paclitaxel, estramustine, and oral etoposide (TEE) (vide infra) starting 28 days after 
conclusion of RT (AS+RT+CT).
Radiation Therapy
RT was started 8 weeks after initiation of AS therapy. Megavoltage equipment with photon 
energies ≥ 6 MV was utilized. CT treatment planning was recommended. All patients on 
both arms received pelvic RT. A dose of 46.8 Gy in 1.8 Gy fractions was utilized to treat the 
prostate and regional lymphatic volumes followed by a prostate boost to deliver 23.4 Gy in 
1.8 Gy fractions to bring the total prostate dose to 70.2 Gy. Based on concerns regarding 
potential bone marrow and gastrointestinal (GI) toxicities, investigators had the option to 
place the superior border of the pelvic lymph node volumes as low as the bottom of the 
sacroiliac (SI) joints. If the seminal vesicles (SV) were involved, an intermediate volume 
including the prostate + SV was treated to 55.8 Gy.
Androgen Suppression Therapy
Prior to the initiation of RT, all patients were treated with total androgen suppression (TAS), 
including an oral non-steroidal anti-androgen (either bicalutamide 50 mg once a day, or 
flutamide 250 mg three times a day), in addition to LHRH agonists (leuprolide or goserelin), 
consistent with design of other RTOG trials of that era.2, 3, 8 The non-steroidal anti-androgen 
was discontinued at the end of RT. All patients continued to receive LHRH agonists for a 
total of 24 months of AS.
Chemotherapy
Patients on AS+RT+CT were randomized to receive 4 cycles of chemotherapy with 
paclitaxel, estramustine, and oral etoposide [TEE] beginning 28 days following completion 
of RT. The regimen included: 1) oral estramustine 280 mg three times a day for the first 14 
of every 21 days, 2) oral etoposide 50 mg/m2 in divided doses twice a day for the first 14 of 
every 21 days, and 3) paclitaxel 135 mg/ m2 intravenously over 1 hour on day 2 of each 21 
day cycle. In addition, after June 3, 2002, the protocol was amended to require 
anticoagulation with warfarin to keep the International Normalized Ratio (INR) >1.5 and < 
2.5. The protocol specified dose modifications with respect to patients with impaired renal 
function and reduced platelet and white blood cell counts.
Statistical Design
The primary endpoint was overall survival (OS), defined as death due to any cause and 
measured from randomization to date of death. Patients were stratified by PSA (≤ 10 vs > 10 
to ≤ 100), tumor stage (T1–2 vs T3–4), Gleason Score (7 vs 8–10), and prior hormones (no 
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vs yes) and then randomized 1:1 to AS+RT or AS+RT+CT using a permuted block 
randomization scheme as defined by Zelen.13 The primary hypothesis was that the addition 
of CT to RTAS would increase OS, corresponding to a 6% improvement at 5 years from 
79% to 85% (Hazard ratio [HR] = 0.67). Using a group sequential design, the original target 
sample size was 1440 patients, in order to provide the required 340 OS events to detect the 
hypothesized increase, with 90% power, a 2-sided significance level of 0.05, and three 
planned interim analyses of efficacy. A toxicity monitoring rule was included to test for an 
unacceptably high toxicity rate of grade 3+ acute toxicity on the AS+RT+CT arm. Based on 
earlier chemotherapy studies, the hypothesized rate was 20%, with the test designed to test 
for a 20% increase to 40%, which would be considered unacceptable. Two-hundred and 
sixty-two patients were required on the AS+RT+CT arm to test this hypothesis, with a 
significance level of 0.025, 90% power, and three interim analyses.
Statistical Methods
All analyses were performed using SAS version 9.2 statistical software (SAS Institute Inc, 
Cary, North Carolina). Secondary endpoints included biochemical failure (BF), using the 
ASTRO definition; local progression (LP), failure – documented clinical local and/or 
regional progression; distant metastases (DM), failure – appearance of distant metastases; 
disease-free survival (DFS), failure – BF, LP, DM, or death due to any cause. All endpoints 
were measured from the date of randomization to first failure or last follow-up for non-
failures. Chemotherapy, hormone therapy, and acute radiotherapy toxicities were graded 
using the CTC version 2.0. Late radiotherapy toxicities were graded using the RTOG/
EORTC Late Toxicity Criteria. The Kaplan-Meier14 approach was used to estimate OS and 
DFS and the log-rank test15 was used to compare treatment arms. Cumulative incidence16 
was used to estimate BF, LP, and DM and the Gray’s test17 was used to compare treatment 
arms. Death was considered a competing risk for BF, LP, and DM. Univariate and 
multivariate Cox proportional hazard models18 were used to obtain hazard ratios (HRs) for 
OS and DFS. Univariate and multivariate Fine-Gray regression models19 were used to 
obtain HRs for BF, LP, and DM. Treatment is coded such that a hazard ratio (HR) > 1 
indicates an increased risk of failure for the AS+RT+CT arm.
Results
The trial opened on January 11, 2000, and closed on October 4, 2004, with a total of 397 of 
the 1440 planned patients entered and randomized: 197 in the AS+RT arm and 200 in the 
AS+RT+CT arm. Of the 397 patients randomized, 17 did not meet the eligibility criteria, 8 
on AS+RT, and 9 on AS+RT+CT. The primary reasons for ineligibility were hormonal 
therapy started > 30 days prior to study entry, and pre-randomization labs not done (Figure 
1: Consort Diagram). The results are reported for all randomized patients, as specified in the 
protocol. All eligible patients were also analyzed, per the protocol, with similar results, not 
reported here. The pretreatment characteristics for all randomized patients are presented in 
Table 1. The treatment arms were well balanced. Median age was 66 years (min-max: 42–
81), median PSA was 22.6 ng/ml (min-max: 0.1–96.4). Sixty-eight percent of patients had 
GS 8–10, 34% were clinical stage T3-T4, and 72% of patients had intercurrent disease. 
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Intercurrent disease included cardiovascular, hypertension, and diabetes. Hypertension was 
the most common.
Accrual to the trial was suspended from April 23, 2002 to June 3, 2002 after the RTOG Data 
Monitoring Committee (DMC) noted an excess of thromboembolic events, and reopened 
after the protocol was modified to include anti-coagulation with warfarin during TEE 
therapy. At that time, a revised monitoring schedule was included based on the rate of grade 
2+ thromboembolic events on the AS+RT+CT arm; a 5% observed rate was hypothesized, 
with the study designed to detect an unacceptable rate of 23%, requiring 30 total patients to 
test and in three stages; if 3 or more patients experienced unacceptable thromboembolic 
toxicity, then the CT regimen would be deemed unacceptable. Subsequently additional 
thromboembolic events were noted, and the DMC suspended accrual to the protocol on July 
30, 2004, which permanently closed to accrual October 4, 2004. The use of estramustine 
was believed to have contributed to the thromboembolic toxicity. Toxicity results were 
evaluated for all 380 eligible patients. Detailed early toxicity results for the trial have been 
previously reported.20 There were three grade 5 toxicities noted on AS+RT+CT. There were 
two cases of death from infection/febrile neutropenia, and one case of death from acute 
myelogenous leukemia (AML) 77 months after randomization. With long-term follow-up, 
there was no excess in late RT toxicity associated with AS+RT+CT arm. Toxicity results for 
randomized patients are summarized in Table 2.
With a median follow-up for all patients of 9.2 years (min-max: 0.4–13.3), 152 of the 340 
primary endpoint events (deaths) per the original statistical design have occurred as of this 
report. 10.0 years is the median follow-up for surviving patients. This corresponds to 62% 
statistical power to detect the hypothesized increase in OS, as compared to the 90% 
statistical power per the original statistical design. There were no statistically significant 
differences noted in any of the pre-specified endpoints of OS, BF, LP, DM, or DFS. A 
summary of 5 and 10-year outcome results for all randomized patients is presented in Table 
3. Ten-year results for all randomized patients by treatment arms (AS+RT vs AS+RT+CT) 
were 65% vs. 63% for OS (Figure 2), 58% vs. 54% for BF (online: Figure A), 11% vs. 7% 
for LP (online: Figure B), 16% vs. 14% for DM (online: Figure C), and 22% vs. 26% for 
DFS (online: Figure D). First failure was BF for 68% of patients, LP for 3% of patients, DM 
for 5% of patients, and death related to protocol treatment for 1% of patients. The bulk of 
failures occurred within 4.5 years of randomization (75%) (online: Table A) and 26% of 
patients had prostate cancer reported as cause of death (online: Table B). The primary causes 
of non-prostate cancer death were cardiovascular or respiratory event (50%) and lung cancer 
(21%). Multivariate analysis revealed that only age, prior hormonal therapy (HT), and the 
presence of intercurrent disease were associated with OS. The significance of prior HT is not 
certain, as subsequent events may have been time shifted as endpoints were calculated from 
the dates of randomization, not the dates of initiation of HT. Treatment arm, PSA, GS, and 
tumor stage were not significant (Table 4).
Many patients did not complete the chemotherapy, or even start chemotherapy, because of 
toxicity or because of the premature closure of the study. Therefore, a post hoc analysis 
regarding the outcomes with respect to the amount of chemotherapy received was 
performed. Of the 200 randomized patients assigned to the chemotherapy arm, 51 (25.5%) 
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received no chemotherapy, 67 (33.5%) received partial chemotherapy (1–3 cycles), and 82 
(41%) received all four cycles of chemotherapy. RT was delivered per protocol or with 
acceptable variation for 92% of randomized patients. When the patients who received partial 
chemotherapy, and the patients who received all four cycles of chemotherapy were 
compared to the control group, there was no significant difference noted in OS, BF, LP, 
DM, or DFS (online: Tables C and D).
Discussion
There were no significant differences noted in OS or in the other pre-specified endpoints of 
BF, LP, DM, or DFS. There was a difference in toxicity, which resulted in premature 
closure of the study. With the sample size of 397 patients, there was no difference noted for 
any of the endpoints, and no difference noted when the subgroup who received the four 
cycles of chemotherapy was compared to control. Multivariate analysis did not suggest that 
there was a benefit of the trial therapy after controlling for tumor stage, Gleason Score, and 
pre-treatment PSA in the model.
Although the trial was negative, this was the first large multicenter randomized phase III 
trial incorporating chemotherapy into the management of non-localized prostate cancer 
treated with RT. There had been skepticism about the ability to accrue patients to a trial 
where non-metastatic patients would be randomized to treatment with CT. The accrual of 
397 patients in the approximately 4 years RTOG 9902 was open demonstrated the feasibility 
of such a trial.
Why was the trial negative? There is a caveat because of the smaller than planned sample 
size, due to the early closure, which reduced the ability to detect the hypothesized difference 
between the treatment arms. All cancer treatment regimens have to balance the therapeutic 
ratio of efficacy over toxicity. In the case of RTOG 9902, there was excess toxicity noted 
with the chemotherapy regimen, with treatment associated mortality. In addition, the 
chemotherapy regimen (TEE) utilized may not have been sufficiently active to have 
produced the initially projected difference in outcomes.
Improvements in systemic therapy options for prostate cancer have occurred since 1999. The 
TEE regimen used in RTOG 9902 would currently be regarded as obsolete. At that time, 
systemic therapy options for patients outside of androgen suppression were limited. In 1999, 
no chemotherapy agents had been demonstrated to result in improved survival for patients 
with hormone refractory prostate cancer. In 2004 docetaxel (Taxotere), was demonstrated to 
improve survival for these patients. The successor trial to RTOG 9902, RTOG 0521, 
employed a similar schema to RTOG 9902, but utilized docetaxel rather than TEE as the 
chemotherapeutic regimen.
RTOG 0521 also updated RT doses and techniques compared with RTOG 9902. There have 
been advances in RT delivery since the trial was designed in 1999. The dose of RT in RTOG 
9902 was 70.2 Gy. Since the trial was designed in 1999, dose escalation in RT has permitted 
an increase in the doses of RT typically utilized.21 Atlases for more consistent definition of 
nodal volumes have also been devised.22 It is possible that with contemporary RT doses, 
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target definition, and delivery techniques, that any difference in treatment outcomes due to 
improved systemic therapy could become more apparent. With the use of docetaxel rather 
than TEE and the use of updated RT doses and techniques, RTOG 0521 completed targeted 
accrual in 2009 with 612 patients. The trial did not require early closure because of toxicity. 
Reporting of 0521 results remains pending.4
The RTOG 9902 trial also helped to provide a database which better defines the natural 
history of high risk prostate cancer treated with LT AS + RT. Age and intercurrent disease 
were identified as significant factors prognostic for overall survival, and as noted previously, 
treatment assignment was not a significant factor. For the control group 10-year data 
showing 65% OS, 22% DFS, 58% BF, 11% LP, and 16% DM can serve as useful 
benchmarks in considering future treatment regimens. Although the majority of recurrences 
occurred in the first 4.5 years, there remains a continued rate of treatment failure after that 
interval.
The RTOG 9902 trial, when compared with the contemporaneous RTOG 9910 trial, which 
focused on intermediate risk patients, confirms the validity of RTOG risk stratification 
between high and intermediate risk. The studies had been designed so that there would be no 
overlap in eligibility criteria between the two trials. In the RTOG 9910 intermediate risk 
prostate cancer trial, there was no difference in prostate cancer deaths between the two arms 
(randomized between 16 weeks of AS+ RT and 36 weeks of AS + RT), there were 12% 
prostate cancer deaths.3 This compares with 26% prostate cancer deaths noted in RTOG 
9902. This suggests that the cohort of patients identified as high risk by RTOG 9902 is 
indeed a group of patients, who, even with long term AS+ RT, have a significant risk of 
death from prostate cancer.
Improving OS and other disease-control outcome measures for patients with high-risk but 
non-metastatic prostate cancer remains an important therapeutic goal. A number of agents 
have been shown to have activity in metastatic prostate cancer. Integration of these agents 
with established therapies, such as long term AS + RT, remains a future therapeutic 
strategy.23
Conclusion
RTOG 9902 showed no statistically significant difference in the outcomes of OS, BF, LP, 
DM, or DFS with the addition of chemotherapy with TEE to a regimen of two years of AS + 
RT. The study was terminated early because of toxicity, and the attendant reduction in the 
sample size may have reduced the ability to have determined significant differences between 
the treatment arms. A subsequent trial, RTOG 0521, completed accrual in 2009 and results 
are pending. RTOG 0521 used docetaxel rather than TEE therapy, as well as updated RT 
doses and techniques. This trial and RTOG 0521 will help to define the role of adjuvant 
chemotherapy in the management of high-risk prostate cancer.
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Summary
NRG Oncology RTOG 99-02 was a 397 patient randomized trial testing the role of 
adjuvant chemotherapy (CT) in conjunction with long term androgen suppression + 
radiotherapy for high-risk prostate cancer patients (PCa). With long-term follow-up, there 
was no significant difference in efficacy endpoints. The trial provides valuable data 
regarding the natural history of high-risk PCa. RTOG 9902 has implications for the 
feasibility of clinical trial accrual and tolerability of CT for patients with PCa.
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Figure 1. 
Consort Diagram
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Figure 2. 
RTOG 9902: Overall Survival by Treatment Arm: All Randomized patients (n=397)
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Table 1
RTOG 9902: Pre-Treatment Characteristics: All Randomized Patients
AS+RT
(n=197)
AS+RT+CT
(n=200)
Total
(n=397)
Age (years)
  Median 65 66.5 66
  Min - Max 42 – 79 42 – 81 42 – 81
  Q1 – Q3 59 – 71 61 – 71.5 60 – 71
PSA (ng/ml)*
  Median 22.5 22.8 22.6
  Min - Max 0.1 – 96.4 1.4 – 95.7 0.1 – 96.4
  Q1 – Q3 9.4 – 39.8 8.9 – 43.6 9.1 – 40.2
  < 10 52 (26.4%) 55 (27.5%) 107 (27.0%)
  ≥ 10 144 (73.1%) 145 (72.5%) 289 (72.8%)
  Unknown 1 (0.5%) 0 (0.0%) 1 (0.3%)
Race
  White 132 (67.0%) 144 (72.0%) 276 (69.5%)
  Hispanic 4 (2.0%) 3 (1.5%) 7 (1.8%)
  African American 56 (28.4%) 51 (25.5%) 107 (27.0%)
  Native Hawaiian or other Pacific Islander 0 (0.0%) 1 (0.5%) 1 (0.3%)
  Asian 2 (1.0%) 1 (0.5%) 3 (0.8%)
  American Indian or Alaska Native 2 (1.0%) 0 (0.0%) 2 (0.5%)
  Unknown 1 (0.5%) 0 (0.0%) 1 (0.3%)
Gleason
  6† 0 (0.0%) 1 (0.5%) 1 (0.3%)
  7 63 (32.0%) 64 (32.0%) 127 (32.0%)
  8–10 134 (68.0%) 135 (67.5%) 269 (67.8%)
Zubrod Performance Status
  0 173 (87.8%) 183 (91.5%) 356 (89.7%)
  1 24 (12.2%) 17 (8.5%) 41 (10.3%)
T-Stage*
  T1 – T2 131 (66.5%) 130 (65.0%) 261 (65.7%)
  T3 – T4 66 (33.5%) 70 (35.0%) 136 (34.3%)
Prior Hormones*
  No 89 (45.2%) 88 (44.0%) 177 (44.6%)
  Yes 108 (54.8%) 112 (56.0%) 220 (55.4%)
Intercurrent Disease
  Absent 47 (23.9%) 60 (30.0%) 107 (27.0%)
  Present 150 (76.1%) 136 (68.0%) 286 (72.0%)
  Unknown 0 (0.0%) 4 (2.0%) 4 (1.0%)
*Stratification factor
Q1 = first quartile; Q3 = third quartile
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†GS=6 was considered ineligible for this trial.
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Table 4
RTOG 9902: Overall Survival: Multivariate Analysis: All Randomized Patients (n=397)
Adjustment
Variables* Comparison
Adjusted HR**
(95% CI) p-value‡
Assigned treatment AS+RT+CT vs. AS+RT 1.06 (0.77, 1.47) 0.71
Prior Hormones Yes vs. No 1.47 (1.06, 2.05) 0.023
Intercurrent Disease Present/unknown vs. Absent 1.59 (1.06, 2.38) 0.026
PSA (ng/ml) ≥ 10 vs. < 10 0.85 (0.58, 1.25) 0.42
Gleason score 8–10 vs. 6–7 0.99 (0.67, 1.48) 0.98
Tumor stage T3–T4 vs. T1–T2 1.21 (0.87, 1.69) 0.26
Age (years) Continuous (unit increase = 5) 1.22† (1.09, 1.37) 0.0007
*All clinically relevant variables were included in the model along with assigned treatment.
**
Hazard Ratio: a hazard ratio of 1 indicates no difference between the two subgroups. The variables were coded such that a HR > 1 indicates an 
increased risk of death for the first level of the variables listed.
†
Interpretation: An increase of 5 years in age corresponds to a 22% increase in the risk of dying.
‡p-value from Chi-square test using the Cox proportional hazards model
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